-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical’s Pharmacovigilance Efforts Commended in Notification by the National Center for Adverse Drug Reaction Monitoring
Category:
发布时间：2025-03-08
【概要描述】
Recently, the National Center for Adverse Drug Reaction Monitoring issued the “Notice on Commending Units for National Adverse Drug Reaction Monitoring and Evaluation in 2024,” recognizing medical institutions, pharmaceutical, medical device, and cosmetic enterprises, and primary-level monitoring agencies that demonstrated outstanding performance in the 2024 national adverse drug reaction monitoring and evaluation efforts. Shijiazhuang Sihua Pharmaceutical Co., Ltd. was included on the list of commended pharmaceutical, medical device, and cosmetic enterprises for 2024.
Recently, the National Center for Adverse Drug Reaction Monitoring issued the “Notice on Commending Units for National Adverse Drug Reaction Monitoring and Evaluation in 2024,” recognizing medical institutions, pharmaceutical, medical device, and cosmetic enterprises, and primary-level monitoring agencies that demonstrated outstanding performance in the 2024 national adverse drug reaction monitoring and evaluation work. Shijiazhuang Sihua Pharmaceutical Co., Ltd. was included on the list of commended pharmaceutical, medical device, and cosmetic enterprises for 2024.
In recent years, Shijiazhuang Sihua Pharmaceutical has placed great emphasis on the monitoring and evaluation of adverse drug reactions, conscientiously fulfilling its principal responsibility. The company has established a comprehensive monitoring network that spans the entire pharmaceutical value chain—research and development, manufacturing, distribution, and clinical use—and leverages a digital platform to collect and analyze adverse reaction data in real time, thereby continuously enhancing its ability to detect risk signals early and issue timely warnings. In 2024, the completeness and timeliness of the adverse reaction reports submitted by the company ranked among the top in the national industry, providing robust support for evidence-based decision-making by drug regulatory authorities.
“This recognition represents a milestone acknowledgment of our company’s pharmacovigilance efforts; it serves not only as encouragement but also as a call to further excel,” said the head of the company’s Pharmacovigilance Center. Moving forward, the center will deepen the collaborative “industry–university–research–clinical” mechanism, promote the in-depth application of artificial intelligence and big data technologies in monitoring, and achieve intelligent prediction and precise control of drug safety risks. In doing so, it aims to explore new approaches to safeguarding public medication safety and comprehensively reinforce the safety baseline for pharmaceuticals.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091